Future in vivo studies performed on the potential lung cancer metastatic PDX (mPDX) models [52] treated with bevacizumab will help uncover cellular and molecular mechanisms regarding how disparate subclones‐derived CTC and CTEC subtypes are related and regulated, and whether EMT as well as EndoMT may play a role in creation of EpCAM+ and/or Vim+ CTCs and CTECs in cancer patients during therapy. The gene discussed is VIM; the disease is lung cancer.